THOMPSON SURGICAL INSTRUMENTS

Additional Manufacturer Narrative

THE DEVICE NOR ANY LOT INFORMATION WAS PROVIDED TO THE MANUFACTURER FOR EVALUATION. WE ARE UNABLE TO DETERMINE THE DEFINITIVE CAUSE OF THE REPORTED EVENT. INITIAL REPORTER (HEALTH PROFESSIONAL) INFORMATION WAS NOT PROVIDED TO MANUFACTURER SO PROVIDE THE NAME AND EMAIL OF THE REPORTER THAT MADE CONTACT WITH THOMPSON SURGICAL INSTRUMENTS. THOMPSON SURGICAL INSTRUMENTS SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PART 803. THIS REPORTING IS ALSO A RESULT OF A CONTAINMENT ACTION OF AN INTERNAL PROCESS NOT REALIZING REPORTING REQUIREMENTS PER INTERNAL FINDINGS WITHIN CORRECTIVE ACTION CAR (B)(4). THOMPSON MADE REASONABLE EFFORTS TO RECEIVE THE PRODUCT BACK AND PROVIDE AS MUCH RELEVANT INFORMATION. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, THOMPSON SURGICAL INSTRUMENTS, OR ITS EMPLOYEES THAT THE DEVICE, THOMPSON SURGICAL INSTRUMENTS, OR ITS EMPLOYEES CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. THOMPSON SURGICAL INSTRUMENTS WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem

ON 2025-07-25 MPXR 1327162 (FOR, HCP, REP): INFORMATION WAS RECEIVED FROM HEALTHCARE PROVIDER (HCP) VIA MANUFACTURER REPRESENTATIVE REGARDING PATIENT HAVING L4/5, L5/S OLIF DUE TO ISOLATION. LEVEL IMPLANTED WAS L4/5, L5/S. IT WAS REPORTED THAT THE COMMON ILIAC VEIN WAS DAMAGED AND A LARGE AMOUNT OF HEMORRHAGING OCCURRED WHICH MAY LEAD TO DEATH OR DISABILITY. BLEEDING WAS OBSERVED GRADUALLY AFTER THE L5/S IMPLANT WAS INSERTED AND ATTEMPTED TO STOP THE BLEEDING WITH THE HEMOSTATIC AGENT FLOSEAL AND SURGE FLOW, BUT HEMOSTASIS COULD NOT BE ACHIEVED. WHEN THE WOUND RETRACTOR WAS REMOVED, A LARGE AMOUNT OF HEMORRHAGING WAS OBSERVED AND THE BLEEDING WAS SUPPRESSED WITH GAUZE, BUT HEMOSTASIS COULD NOT BE ACHIEVED, SO A SURGEON FROM CARDIOVASCULAR SURGERY WAS CONTACTED TO COME. THE POSITION WAS CHANGED FROM LATERAL TO SUPINE AND THEN SWITCHED TO THE CARDIOVASCULAR SURGEON, THE BLEEDING SITE IS SPECIFIED AND THEN SUTURED TO STOP THE BLEEDING. BLOOD PRESSURE DROPPED TO 50 MIDWAY, BUT RECOVERED. ACCORDING TO THE CARDIOVASCULAR SURGEON, VEIN WAS PUSHED SLIGHTLY, BUT IT WOULD PROBABLY BE OKAY. THE PATIENT MIGHT EXPERIENCE SWELLING AFTER THE SURGERY, BUT IT WILL RETURN TO NORMAL. ACCORDING TO THE SURGEON, THE BLEEDING GRADUALLY OCCURRED WHEN THE DEVICE WAS INSERTED WITH A HAMMER DURING THE TRIAL. A LITTLE MORE CAME OUT WHEN THE REAL THING OR WHEN THE SCREW WAS INSERTED. IT MIGHT HAVE RUPTURED THE BLOOD VESSEL WHEN THE SPACE BETWEEN THE VERTEBRAE WAS WIDENED DURING THE TRIAL. FURTHERMORE, THE SURGEON AROUND THE PATIENT WAS NOT ABLE TO DETACH PROPERLY, AND MIGHT HAVE BEEN CAUGHT WITH THE RETRACTOR. THE CARDIOVASCULAR SURGEON SAID THAT THE BACK SIDE OF THE LATERAL WALL OF THE COMMON ILIAC VEIN HAD RUPTURED. THERE WAS A DELAY OF GREATER THAN 60 MINUTES OCCURRED AND NO FURTHER COMPLICATIONS OR SYMPTOMS REPORTED. ON 2025-JUL-31_ARED (REP): ADDITIONAL INFORMATION WAS RECEIVED VIA MANUFACTURER REPRESENTATIVE THAT THE CAUSE OF THE EVENT IS UNKNOWN, BUT HOWEVER IT IS CONSIDERED AS USER ERROR. IT WAS OBSERVED THAT THAT THE BLEEDING STARTED GRADUALLY AFTER THE DEVICES WERE INSERTED. THERE MAY BE A POSSIBILITY OF THE BLOOD VESSEL TORN WHEN THE DEVICES WERE INSERTED, BUT THERE ARE NO COMPLAINTS ABOUT THE IMPLANT. THE BLADE MAY HAVE CAUGHT A BLOOD VESSEL. THERE IS NO PLAN TO REMOVE THE PRODUCTS. THE PATIENT SEEMS TO BE IN A STATE WHERE HE CANNOT MAKE PREDICTIONS WHILE STILL IN THE ICU.